Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Apr 12, 2021 (5 years ago)

Cephalexin for Oral Suspension

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Impurities/degradation specifications: Repackager recall due to Out of Specification detected by manufacturer for Individual Unidentified Impurity found during related substance test analysis of Cephalexin

Cause type: Impurity / degradation

An impurity or degradation product above its limit - other than nitrosamines. Unexpected substances in a batch can make it unsafe or less effective, even when the active ingredient is present. All impurity / degradation recalls.

What was recalled

Cephalexin for Oral Suspension, Generic for Keflex, USP, Powder for Oral Suspension, 250 mg/5mL, Pkg Size 100, Rx only, Repackaged by Preferred Pharmaceuticals, Inc., Mfg: Ascend Laboratories, LLC, NDC #: 68788-7529-1,

Affected NDC 68788-7529-01

Compare with the code on your package — it is the most precise check available.

Drug: Cephalexin Category: Antibiotic

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Cephalexin
NDC 68788-7529
250 mg/5mL For Suspension
Oral
Preferred Pharmaceuticals, Inc. Rx
Recalling firm
Preferred Pharmaceuticals, Inc.
Origin
CA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0342-2021 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Cephalexin recalls

See all
Class II · Moderate risk

Cephalexin for Oral Suspension

Failed Impurities/Degradation Specifications An out-of-specification result was observed in the related substance test at the sixth month of stability analysis. The individual impurity was identified to be Cephalexin Glucose Adduct.

Ongoing Impurity / degradation Ascend Laboratories, LLC NDC 67877-544-68 D-0469-2025
Class II · Moderate risk

Cephalexin for Oral Suspension

Failed Impurities/Degradation Specifications An out-of-specification result was observed in the related substance test at the sixth month of stability analysis. The individual impurity was identified to be Cephalexin Glucose Adduct.

Ongoing Impurity / degradation Ascend Laboratories, LLC NDC 67877-544-88 D-0468-2025
Class III · Low risk

Cephalexin for Oral Suspension

Labeling: Not Elsewhere Classified: Back Label states 'Each contains: cephalexin monohydrate, USP equivalent to 5g' instead of Each Bottle contains: cephalexin monohydrate, USP equivalent to 10g'

Ongoing Labeling / mix-up Bryant Ranch Prepack, Inc. NDC 63629-9207-1 D-0540-2024
Class III · Low risk

Cephalexin for Oral Suspension

Labeling: Not Elsewhere Classified: Back Label states Each contains: cephalexin monohydrate, USP equivalent to 5g' on the back label instead of Each Bottle contains: cephalexin monohydrate, USP equivalent to 5g'

Ongoing Labeling / mix-up Bryant Ranch Prepack, Inc. NDC 63629-9206-1 D-0539-2024
Class III · Low risk

Cephalexin for Oral Suspension

Labeling: Not Elsewhere Classified: Back Label states 'Each contains: cephalexin monohydrate, USP equivalent to 5g' instead of Each Bottle contains: cephalexin monohydrate, USP equivalent to 10g'

Ongoing Labeling / mix-up Bryant Ranch Prepack, Inc. NDC 63629-8858-1 D-0538-2024

Other recalls by Preferred Pharmaceuticals, Inc.

All 2021 recalls
Class II · Moderate risk

Ondansetron ODT Tablets

Defective container: Preferred Pharmaceuticals received a letter from the manufacturer Glenmark, that the blister packs are not fully sealed and tablets falling out. Preferred Pharmaceuticals purchased the finished product and repackaged the product for sale.

Ongoing Packaging defect Preferred Pharmaceuticals, Inc. NDC 68788-8666-01 D-0239-2026
Class II · Moderate risk

Ibuprofen Tablets

Failed Impurities/Degradation Specifications - at 18-month Stability testing

Ongoing Impurity / degradation Preferred Pharmaceuticals, Inc. NDC 68788-9110-03 D-0647-2024